Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery

• Status: Not yet recruiting
• Trial end date: 2023-08-29
• Target enrollment: 0
• Participant gender: All

Summary

In multiple previous studies that have explored the use of dexmedetomidine in transsphenoidal tumor resection surgery, dexmedetomidine showed many beneficial effects like reducing the requirement of analgesics and anesthetics, improving hemodynamic stability and decreasing the emergence time, extubation time and visual analog scale at emergence. Therefore, the investigators hypothesized that dexmedetomidine would decrease neuroendocrine stress response and improve the quality of postoperative recovery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Non-functioning patients undergoing endoscopic transsphenoidal tumor surgery under general anesthesia

Exclusion Criteria:

• Patients who do not agree to participate in the study

• Patients with contraindication to dexmedetomidine

• Patients with previous history of endoscopic transsphenoidal tumor surgery

• Patients who take anticoagulants or have bleeding disorder

• Patients with conduction block or cardiovascular disease

• Patients with psychiatric disease such as dementia, delirium

• Patients have difficulty filling out the QoR-15 questionnaire

• Pregnant or lactating women

• Patients who have allergies to propofol, remifentanil, fentanyl or rocuronium

• Patients with myasthenia gravis or myasthenic syndrome